OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Markowski on the Evaluation of Sabizabulin in mCRPC

July 11th 2022

Mark C. Markowski, MD, PhD, discusses the evaluation of sabizabulin in a phase 1b/2 trial in metastatic castration-resistant prostate cancer.

Women in Oncology: Career Obstacles Turned Into Opportunities

July 11th 2022

Judith Karp, MD; Azra Raza, MD; and Michelle M. Le Beau, PhD, share the challenges they chose to mold into career goals, including developing a new technology to study cell cytokinetics, identifying gene phenotypes, and recognizing that leukemia diseases stem from the same root issues in DNA.

Dr. Jonasch on the Investigation of Belzutifan in ccRCC

July 8th 2022

Eric Jonasch, MD, discusses the investigation of belzutifan (Welireg) in clear cell renal cell carcinoma.

Dr. Hays on the Importance of Genetic Testing in Colorectal Cancer

July 8th 2022

John L. Hays, MD, PhD, discusses the importance of genetic testing in colorectal cancer.

Women in Oncology: How Leukemia Treatment has Changed and Stayed Stagnant Over the Years

July 8th 2022

Judith Karp, MD; Azra Raza, MD; and Michelle M. Le Beau, PhD, highlight the decades-long evolution of the leukemia field and express challenges such as defining the causes of leukemia and developing therapies to treat the disease and mitigate adverse effects like bone pain.

Dr. Rajdev on Detecting HER2 Positivity in GI Cancer

July 7th 2022

Lakshmi Rajdev, MD, MS, discusses detecting HER2 positivity in patients with gastrointestinal cancers.

Dr. Brenner on the Role of Trastuzumab Deruxtecan in Gastric Cancer

July 7th 2022

Warren S. Brenner, MD, discusses the utilization of fam-trastuzumab deruxtecan-nxki (Enhertu) as a HER2-directed therapy in gastric cancer.

Dr. Elamin on NRG1 Fusions in Solid Tumors

July 7th 2022

Yasir Y. Elamin, MD, discusses NRG1 fusions in solid tumors.

Dr. Vidal on the Lasting Impact of the KATHERINE Trial in HER2-Positive Breast Cancer

July 7th 2022

Gregory Vidal, MD, PhD, discusses the impact of the phase 3 KATHERINE trial in HER2-positive breast cancer.

Dr. Sullivan on the Examination of Tebentafusp in Uveal Melanoma

July 6th 2022

Ryan J. Sullivan, MD, discusses the examination of tebentafusp-tebn in uveal melanoma.

Dr. Rampal on the Potential Utilization of Navtemadlin in Relapsed/Refractory AML and MPNs

July 6th 2022

Raajit K. Rampal, MD, PhD, discusses the potential utilization of navtemadlin in relapsed/refractory acute myeloid leukemia and patients with blast phase myeloproliferative neoplasm in a phase 1b/2 trial.

Dr. Shah on the Importance of Genetic Testing in GI Cancer

July 6th 2022

Manish A Shah, MD, discusses the importance of genetic testing in gastrointestinal cancer.

Dr. Park on the Role of Cemiplimab in Advanced Basal Cell Carcinoma

July 1st 2022

Soo Park, MD, discusses the role of cemiplimab-rwlc (Libtayo) in advanced basal cell carcinoma.

Dr. Yoon on Updated Data on Tislelizumab Plus Chemotherapy in ESCC

June 30th 2022

Harry H. Yoon, MD, discusses updated findings from the phase 3 RATIONALE-306 trial in esophageal squamous cell carcinoma.

Dr. Vogel on the OS Benefit of Durvalumab/Tremelimumab in Unresectable HCC

June 30th 2022

Arndt Vogel, MD, discusses the outcomes of the phase 3 HIMALAYA trial in unresectable hepatocellular carcinoma.

Dr. Luke on the Importance of a Multidisciplinary Approach in Basal Cell Carcinoma

June 30th 2022

Jason Luke, MD, FACP, discusses the importance of a multidisciplinary approach in basal cell carcinoma.

Dr. Monk on the Need for Molecular Testing in Ovarian Cancer

June 30th 2022

Bradley J. Monk, MD, FACS, FACOG, discusses the importance of molecular testing in ovarian cancer.

Dr. Schwartzberg on the Use of Myriad Genomic Testing in Cancer Care

June 30th 2022

Lee S. Schwartzberg, MD, FACP, discusses the utilization of genomics in cancer care.

Dr. Lipson on the Current Treatment Landscape of Basal Cell Carcinoma

June 30th 2022

Evan J. Lipson, MD, discusses the current treatment landscape in locally advanced, unresectable, or metastatic basal cell carcinoma.

Dr. Kim on the Future Role of Y-90 in Patients with Unresectable HCC

June 29th 2022

Edward Kim, MD, discusses the future role of Y-90 in patients with unresectable hepatocellular carcinoma.